Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$22.44 USD
-0.56 (-2.43%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $22.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Intellia Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 912 | 1,193 | 749 | 597 | 280 |
Receivables | 36 | 4 | 2 | 2 | 5 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 50 | 20 | 19 | 17 | 5 |
Total Current Assets | 998 | 1,217 | 769 | 617 | 289 |
Net Property & Equipment | 33 | 28 | 21 | 16 | 18 |
Investments & Advances | 112 | 102 | 395 | 0 | 5 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 43 | 41 | 30 | 5 | 3 |
Total Assets | 1,301 | 1,520 | 1,294 | 676 | 334 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 5 | 10 | 10 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 67 | 61 | 43 | 26 | 13 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 22 | 44 | 64 | 23 | 13 |
Total Current Liabilities | 115 | 127 | 126 | 64 | 36 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 39 | 20 | 63 | 51 | 16 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 24 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 251 | 285 | 254 | 149 | 64 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,711 | 2,420 | 1,746 | 962 | 570 |
Retained Earnings | -1,658 | -1,177 | -703 | -435 | -301 |
Other Equity | -2 | -7 | -3 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1,050 | 1,236 | 1,040 | 527 | 270 |
Total Liabilities & Shareholder's Equity | 1,301 | 1,520 | 1,294 | 676 | 334 |
Total Common Equity | 1,050 | 1,236 | 1,040 | 527 | 270 |
Shares Outstanding | 89.50 | 78.60 | 73.40 | 59.00 | 48.80 |
Book Value Per Share | 11.73 | 15.72 | 14.17 | 8.93 | 5.53 |
Fiscal Year End for Intellia Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 691 | 791 | 912 | 855 | 908 |
Receivables | 12 | 36 | 36 | 6 | 5 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 54 | 56 | 50 | 32 | 26 |
Total Current Assets | 757 | 884 | 998 | 893 | 940 |
Net Property & Equipment | 30 | 32 | 33 | 34 | 33 |
Investments & Advances | 249 | 162 | 112 | 155 | 186 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 50 | 71 | 43 | 42 | 41 |
Total Assets | 1,192 | 1,260 | 1,301 | 1,243 | 1,323 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 19 | 14 | 7 | 4 | 12 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 45 | 43 | 67 | 58 | 50 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 22 | 22 | 22 | 13 | 22 |
Total Current Liabilities | 105 | 98 | 115 | 92 | 100 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 28 | 33 | 39 | 13 | 13 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 220 | 223 | 251 | 206 | 218 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,885 | 2,803 | 2,711 | 2,567 | 2,513 |
Retained Earnings | -1,913 | -1,766 | -1,658 | -1,526 | -1,404 |
Other Equity | -1 | -1 | -2 | -4 | -4 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 971 | 1,036 | 1,050 | 1,037 | 1,105 |
Total Liabilities & Shareholder's Equity | 1,192 | 1,260 | 1,301 | 1,243 | 1,323 |
Total Common Equity | 971 | 1,036 | 1,050 | 1,037 | 1,105 |
Shares Outstanding | 96.40 | 96.40 | 89.50 | 88.40 | 88.40 |
Book Value Per Share | 10.07 | 10.75 | 11.73 | 11.74 | 12.50 |